retatrutide eli lilly phase 2 results Lilly's triple agonist delivers up to 71.2 lbs of weight loss Eli Lilly's triple agonist retatrutide

It isn't approved for treating obesity, but during tirzepatide diabetes trials, researchers noted people who got tirzepatide lost much more weight than those on standard diabetes therapy

Practical tips around comfort and technique support better consistency over time

Weight Medics

Improving Aesthetic Results for GLP-1 Patients with Sofwave and Pure Impact Date Written by James Bartholomeusz Revised by Jessica Weiser, MD GLP-1 therapies are driving unprecedented weight loss in patients, but they frequently result in a variety of issues ranging from muscle atrophy to skin laxity

Effects of Growth Hormone Administration on Body Composition During Dietary Restriction. Journal of Clinical Endocrinology and Metabolism

115117 Recent literature suggests that EBDs also modulate epigenetic changes that lead to sustained rejuvenation and remodeling